Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study.
Cohort studies
Fibrosis
Lung
Pulmonary emphysema
Tomography
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
20 Oct 2020
20 Oct 2020
Historique:
received:
13
07
2020
accepted:
12
10
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
21
8
2021
Statut:
epublish
Résumé
Combined pulmonary fibrosis and emphysema (CPFE) is a heterogeneous clinico-radiological syndrome without a consensus definition. There are limited data on the relation between the amount of parenchymal fibrosis and prognosis. In this study, we assessed the prognostic implications of the extent of fibrosis assessed by an automated quantitative computed tomography (CT) technique and the radiological and functional change over time in patients with a broad spectrum of fibrotic interstitial lung diseases (ILDs) encountered in a real-world setting. We conducted a single-centre, retrospective study of 228 consecutive patients with CPFE, encountered from 2007 to 2015 at Kameda Medical Center, Chiba, Japan. We investigated the prognostic value of automated CT fibrosis quantification and the subsequent course of CPFE. Among 228 patients with CPFE, 89 had fibrosis affecting < 5% of their lungs, 54 had 5 to < 10% fibrosis, and 85 had ≥ 10% fibrosis at the time of diagnosis. Lower volume of fibrosis correlated with lower rates of mortality and acute exacerbation (p < 0.001). In particular, among those with < 5% fibrosis, only 4.5% died and none experienced acute exacerbation during follow-up, whereas 57.6% and 29.4% of those with ≥ 10% fibrosis experienced death and acute exacerbation, respectively. Although, the ≥ 10% fibrosis group had the poorest overall survival as well as the highest incidence of acute exacerbation, the incidence of decline in pulmonary function tests, change per year in total lung volume, and progression of fibrosis on chest CT was highest in the 5 to < 10% fibrosis group. The Cox proportional hazard model for CPFE progression (defined by composite criteria of death, acute exacerbation, and decline in forced vital capacity or diffusing capacity) showed fibrosis proportion was a risk factor independent of age, sex, smoking pack-years, the Charlson Comorbidity Index, lung cancer, connective tissue disease, and idiopathic pulmonary fibrosis. Less severe (< 5%) fibrosis at baseline was associated with disease stability and better prognosis compared to more severe fibrosis in CPFE occurring with fibrotic ILDs. Further studies including a validation cohort will be needed. Trial Registration Retrospectively registered.
Sections du résumé
BACKGROUND
BACKGROUND
Combined pulmonary fibrosis and emphysema (CPFE) is a heterogeneous clinico-radiological syndrome without a consensus definition. There are limited data on the relation between the amount of parenchymal fibrosis and prognosis. In this study, we assessed the prognostic implications of the extent of fibrosis assessed by an automated quantitative computed tomography (CT) technique and the radiological and functional change over time in patients with a broad spectrum of fibrotic interstitial lung diseases (ILDs) encountered in a real-world setting.
METHODS
METHODS
We conducted a single-centre, retrospective study of 228 consecutive patients with CPFE, encountered from 2007 to 2015 at Kameda Medical Center, Chiba, Japan. We investigated the prognostic value of automated CT fibrosis quantification and the subsequent course of CPFE.
RESULTS
RESULTS
Among 228 patients with CPFE, 89 had fibrosis affecting < 5% of their lungs, 54 had 5 to < 10% fibrosis, and 85 had ≥ 10% fibrosis at the time of diagnosis. Lower volume of fibrosis correlated with lower rates of mortality and acute exacerbation (p < 0.001). In particular, among those with < 5% fibrosis, only 4.5% died and none experienced acute exacerbation during follow-up, whereas 57.6% and 29.4% of those with ≥ 10% fibrosis experienced death and acute exacerbation, respectively. Although, the ≥ 10% fibrosis group had the poorest overall survival as well as the highest incidence of acute exacerbation, the incidence of decline in pulmonary function tests, change per year in total lung volume, and progression of fibrosis on chest CT was highest in the 5 to < 10% fibrosis group. The Cox proportional hazard model for CPFE progression (defined by composite criteria of death, acute exacerbation, and decline in forced vital capacity or diffusing capacity) showed fibrosis proportion was a risk factor independent of age, sex, smoking pack-years, the Charlson Comorbidity Index, lung cancer, connective tissue disease, and idiopathic pulmonary fibrosis.
CONCLUSIONS
CONCLUSIONS
Less severe (< 5%) fibrosis at baseline was associated with disease stability and better prognosis compared to more severe fibrosis in CPFE occurring with fibrotic ILDs. Further studies including a validation cohort will be needed. Trial Registration Retrospectively registered.
Identifiants
pubmed: 33081788
doi: 10.1186/s12931-020-01545-3
pii: 10.1186/s12931-020-01545-3
pmc: PMC7576807
doi:
Types de publication
Journal Article
Pragmatic Clinical Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Subventions
Organisme : NIAMS NIH HHS
ID : K23 AR076453
Pays : United States
Références
Respirology. 2014 Feb;19(2):239-245
pubmed: 25198924
Chest. 2012 Jan;141(1):222-231
pubmed: 22215830
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Nat Rev Rheumatol. 2019 Oct;15(10):581-596
pubmed: 31455869
Ann Intern Med. 2007 Oct 16;147(8):573-7
pubmed: 17938396
Proc Am Thorac Soc. 2006 Jun;3(4):285-92
pubmed: 16738191
Am J Respir Crit Care Med. 2003 Sep 1;168(5):531-7
pubmed: 12791580
Respir Med. 2019 Jan;146:106-112
pubmed: 30665507
Arthritis Rheum. 2011 Jan;63(1):295-304
pubmed: 20936629
Respir Res. 2019 May 23;20(1):101
pubmed: 31122243
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Respir Med. 1990 Sep;84(5):365-9
pubmed: 2247666
Am J Respir Crit Care Med. 2017 Nov 1;196(9):1162-1171
pubmed: 28657784
PLoS One. 2014 Sep 09;9(9):e107476
pubmed: 25203455
Eur Respir J. 2005 Oct;26(4):586-93
pubmed: 16204587
Eur Respir J. 2017 Jul 5;50(1):
pubmed: 28679618
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1514-1522
pubmed: 27314401
Eur Respir J. 2017 Jul 5;50(1):
pubmed: 28679612
Chest. 2014 Apr;145(4):723-728
pubmed: 24114524
Eur Respir J. 2014 Jan;43(1):204-12
pubmed: 23563264
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Am J Respir Crit Care Med. 1999 Feb;159(2):519-25
pubmed: 9927367
Chest. 2018 Aug;154(2):394-408
pubmed: 29222007
Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619888119
pubmed: 31722622
Am J Respir Crit Care Med. 2002 Jan 15;165(2):277-304
pubmed: 11790668
Eur Respir J. 2015 Oct;46(4):976-87
pubmed: 26160873
J Thorac Imaging. 2013 Sep;28(5):298-307
pubmed: 23966094
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1382-9
pubmed: 21940789
Eur J Radiol. 2015 Jul;84(7):1413-8
pubmed: 25868675